Lung Cancer

Immunotherapy plus chemo combo shows survival benefit in extensive SCLC

Atezolizumab added to carboplatin and etoposide continues to demonstrate an improved overall survival benefit for patients with extensive-stage small-cell lung cancer (ES-SCLC), updated results from the IMpower133 trial shows. Presenting the latest findings to ESMO 2019 congress, Dr. Martin Reck from Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany said there was ...

Already a member?

Login to keep reading.

© 2022 the limbic